Alvotech: EMA Accepts Marketing Application for Proposed Biosimilar to Eylea

 Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma, a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, and rare disease medicines in Europe, today announced that the European Medicines Agency (EMA) has accepted a Marketing Authorization Application for AVT06, Alvotech’s proposed biosimilar to Eylea® (aflibercept). The process to obtain marketing authorization could be completed in the third quarter of 2025.

https://www.globenewswire.com/news-release/2024/08/15/2930697/0/en/European-Medicines-Agency-Confirms-Acceptance-of-Marketing-Application-for-AVT06-a-Proposed-Biosimilar-to-Eylea-aflibercept.html